Overview

• CEO Umang Vohra announced plans to launch a dedicated weight management division in India to address rising obesity and diabetes rates.
• The company has in-licensed Sanofi’s India CNS portfolio, including the anti-epileptic brand Frisium, to bolster its neurological drug lineup.
• Cipla intends to pursue further in-licensing deals or acquisitions in niche CNS indications such as ADHD and Parkinson’s disease.
• Its antimicrobial resistance strategy is shifting from volume-based sales to an innovation-driven model with four novel AMR candidates in development.
• Robust FY25 results—Rs 27,548 crore in revenue and Rs 5,272 crore in net profit—are funding these strategic expansions.